Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
2018
9.4K+
LTM Revenue $4.4B
LTM EBITDA $893M
$8.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Elanco has a last 12-month revenue of $4.4B and a last 12-month EBITDA of $893M.
In the most recent fiscal year, Elanco achieved revenue of $4.4B and an EBITDA of $1.4B.
Elanco expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Elanco valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $4.4B | $4.4B | XXX | XXX | XXX |
Gross Profit | $2.5B | $2.5B | XXX | XXX | XXX |
Gross Margin | 57% | 56% | XXX | XXX | XXX |
EBITDA | -$224M | $1.4B | XXX | XXX | XXX |
EBITDA Margin | -5% | 31% | XXX | XXX | XXX |
Net Profit | -$78.0M | -$1.2B | XXX | XXX | XXX |
Net Margin | -2% | -28% | XXX | XXX | XXX |
Net Debt | $5.5B | $5.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Elanco's stock price is $9.
Elanco has current market cap of $4.3B, and EV of $8.2B.
See Elanco trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$8.2B | $4.3B | XXX | XXX | XXX | XXX | $0.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Elanco has market cap of $4.3B and EV of $8.2B.
Elanco's trades at 1.8x LTM EV/Revenue multiple, and 9.1x LTM EBITDA.
Analysts estimate Elanco's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Elanco and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $8.2B | XXX | XXX | XXX |
EV/Revenue | 1.8x | XXX | XXX | XXX |
EV/EBITDA | 5.9x | XXX | XXX | XXX |
P/E | 12.7x | XXX | XXX | XXX |
P/E/Growth | 0.7x | XXX | XXX | XXX |
EV/FCF | 21.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpElanco's NTM/LTM revenue growth is 2%
Elanco's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Elanco's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Elanco's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Elanco and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 0% | XXX | XXX | XXX | XXX |
EBITDA Margin | 31% | XXX | XXX | XXX | XXX |
EBITDA Growth | -718% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elanco acquired XXX companies to date.
Last acquisition by Elanco was XXXXXXXX, XXXXX XXXXX XXXXXX . Elanco acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Elanco founded? | Elanco was founded in 2018. |
Where is Elanco headquartered? | Elanco is headquartered in United States of America. |
How many employees does Elanco have? | As of today, Elanco has 9.4K+ employees. |
Who is the CEO of Elanco? | Elanco's CEO is Mr. Jeffrey N. Simmons. |
Is Elanco publicy listed? | Yes, Elanco is a public company listed on NYS. |
What is the stock symbol of Elanco? | Elanco trades under ELAN ticker. |
When did Elanco go public? | Elanco went public in 2018. |
Who are competitors of Elanco? | Similar companies to Elanco include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Elanco? | Elanco's current market cap is $4.3B |
What is the current revenue of Elanco? | Elanco's last 12-month revenue is $4.4B. |
What is the current EBITDA of Elanco? | Elanco's last 12-month EBITDA is $893M. |
What is the current EV/Revenue multiple of Elanco? | Current revenue multiple of Elanco is 1.8x. |
What is the current EV/EBITDA multiple of Elanco? | Current EBITDA multiple of Elanco is 9.1x. |
What is the current revenue growth of Elanco? | Elanco revenue growth between 2023 and 2024 was 0%. |
Is Elanco profitable? | Yes, Elanco is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.